OJD  Vol.3 No.5 , November 2014
Paroxetine Increased the Serum Estrogen in Postmenopausal Women with Depressive and Anxiety Symptoms
Abstract: Objective: Both of selective serotonin reuptake inhibitors (SSRIs) and estrogen can modulate emotion and cognition function in post-menopause women, moreover SSRIs can influence estrogen system in rats and aquatic wildlife but most of them for reproductive ability. The aim of this study was to investigate the possible relationship between SSRI, estrogen, and emotion and cognition in post-menopause women with anxiety and depressive symptoms .Methods: A double-blind, randomized controlled trials of Paroxetine, an SSRI (n = 44), versus placebo (n = 38) for 6 months in post-menopausal women with anxiety and depressive symptoms. For screening anxiety, depression and mild cognitive impairment (MCI), we use the Hamilton Anxiety Rating Scale (HAM-A), the Hamilton Depression Rating Scale (HAM-D) and the Chinese Version of the Montreal cognitive assessment (MoCA-CV). And sex hormones were measured by ELASE method which is serum estradiol (E2), follicle stimulating hormone (FSH) and luteinizing hormone (LH). Results: Paroxetine increased serum E2 and decreased LH, FSH significantly (P < 0.05). Meanwhile, HAM-A and HAM-D scores declined and MoCA-CV score raised by Paroxetine (P < 0.05). We also found that a negative association between E2 and scores of HAM-A and HAM-D at pre-treatment and post-treatment of Paroxetine (HAM-A: R = ?0.27, R = ?0.24; HAM-D: R = ?0.65, R = ?0.37), while a positive correlation between E2 and MoCA-CV scores (R = 0.52, R = 0.47). Conclusions: This founding suggests that SSRI can increase serum estrogen levels and the change of estrogen may be one of mechanism in SSRI’s improve emotion and cognitive function in post-menopausal women.
Cite this paper: Zhou, B. , Xie, S. , Hu, J. , Sun, X. , Guan, H. and Deng, Y. (2014) Paroxetine Increased the Serum Estrogen in Postmenopausal Women with Depressive and Anxiety Symptoms. Open Journal of Depression, 3, 184-194. doi: 10.4236/ojd.2014.35022.

[1]   Barch, D. M., D’Angelo, G., Pieper, C. et al. (2012) Cognitive Improvement Following Treatment in Late-Life Depression: Relationship to Vascular Risk and Age of Onset. American Journal of Geriatric Psychiatry, 20, 682-690.

[2]   Brosen, K. (1995). Drug Interactions and the Cytochrome P450 System: The Role of Cytochrome P450 1A2. Clinical Pharmacokinetics, 29, 20-25.

[3]   Colenda, C. C., Legault, C., Rapp, S. R. et al. (2010). Psychiatric Disorders and Cognitive Dysfunction among Older, Postmenopausal Women: Results from the Women’s Health Initiative Memory Study. American Journal of Geriatric Psychiatry, 18, 177-186.

[4]   Cooper, J. E. (1989). An Overview of the Prospective ICD-10 Classification of Mental Disorders. The British Journal of Psychiatry. Supplement, 4, 21-23.

[5]   Cubeddu, A., Giannini, A., & Bucci, F. et al. (2010). Paroxetine Increases Brain-Derived Neurotrophic Factor in Postmenopausal Women. Menopause: The Journal of The North American Menopause Society, 17, 338-343.

[6]   Cubeddu, A., Giannini, A., Bucci, F. et al. (2010). Paroxetine Increases Brain-Derived Neurotrophic Factor in Postmenopausal Women. Menopause, 17, 338-343.

[7]   Estrada-Camarena, E., Lopez-Rubalcava, C., & Vega-Rivera, N. (2010). Antidepressant Effects of Estrogens: A Basic Approximation. Behavioural Pharmacology, 21, 451-464.

[8]   Fales, C. L., Barch, D. M., Rundle, M. M. et al. (2009). Antidepressant Treatment Normalizes Hypoactivity in Dorsolateral Prefrontal Cortex during Emotional Interference Processing in Major Depression. Journal of Affective Disorders, 112, 206-211.

[9]   Foran, C. M., Weston, J., Slattery, M., Brooks, B. W., & Huggett, D. B. (2004). Reproductive Assessment of Japanese Medaka (Oryzias latipes) Following a Four-Week Fluoxetine (SSRI) Exposure. Archives of Environmental Contamination and Toxicology, 46, 511-517.

[10]   Hall, J. E. (2007). Neuroendocrine Changes with Reproductive Aging in Women. Seminars in Reproductive Medicine, 25, 344-351.

[11]   Hamilton, M. (1959). The Assessment of Anxiety States by Rating. British Journal of Medical Psychology, 32, 50-55.

[12]   Harvey, A., & Preskorn, S. (1996). Cytochrome P450 Enzymes: Interpretation of Their Interactions with Selective Serotonin Reuptake Inhibitors. Part II. Journal of Clinical Psychopharmacology, 16, 345-355.

[13]   Korczyn, A. D., & Halperin, I. (2009). Depression and Dementia. Journal of the Neurological Sciences, 283, 139-142.

[14]   Kornstein, S. G., Schatzberg, A. F., Thase, M. E., Yonkers, K. A., McCullough, J. P., Keitner, G. I. et al. (2000). Gender Differences in Treatment Response to Sertraline versus Imipramine in Chronic Depression. American Journal of Psychiatry, 157, 1445-1452.

[15]   Lister, A., Regan, C., Van Zwol, J., & Van Der Kraak, G. (2009). Inhibition of Egg Production in Zebrafish by Fluoxetine and Municipal Effluents: A Mechanistic Evaluation. Aquatic Toxicology, 95, 320-329.

[16]   Maswood, S., Truitt, W., Hotema, M., Caldarola-Pastuszka, M., & Uphouse, L. (1999). Estrous Cycle Modulation of Extracellular Serotonin in Mediobasal Hypothalamus: Role of the Serotonin Transporter and Terminal Autoreceptors. Brain Research, 831, 146-154.

[17]   Mennigen, J. A., Lado, W. E., Zamora, J. M., Duarte-Guterman, P., Langlois, V. S., Metcalfe, C. D. et al. (2010). Waterborne Fluoxetine Disrupts the Reproductive Axis in Sexually Mature Male Goldfish, Carassius auratus. Aquatic Toxicology, 100, 354-364.

[18]   Million Women Study Collaborators (2003). Breast Cancer and Hormone-Replacement Therapy in the Million Women Study. Lancet, 362, 419-427.

[19]   Mondal, S., Saha, I., Das, S., Ganguly, A., Das, D., & Tripathi, S. K. (2013). A New Logical Insight and Putative Mechanism behind Fluoxetine-Induced Amenorrhea, Hyperprolactinemia and Galactorrhea in a Case Series. Therapeutic Advances in Psychopharmacology, 3, 322-334.

[20]   Numakawa, T., Suzuki, S., Kumamaru, E., Adachi, N., Richards, M., & Kunugi, H. (2010). BDNF Function and Intracellular Signaling in Neurons. Histology and Histopathology, 25, 237-258.

[21]   Numakawa, T., Yokomaku, D., Richards, M., Hori, H., Adachi, N., & Kunugi, H. (2010). Functional Interactions between Steroid Hormones and Neurotrophin BDNF. World Journal of Biological Chemistry, 1, 133-143.

[22]   Pae, C. U., Mandelli, L., Han, C., Ham, B. J., Masand, P. S., Patkar, A. A. et al. (2008). Do Estradiol Levels Influence on the Cognitive Function during Antidepressant Treatments in Post-Menopausal Women with Major Depressive Disorder? A Comparison with Pre-Menopausal Women. Neuro Endocrinology Letters, 29, 500-506.

[23]   Paleacu, D., Shutzman, A., Giladi, N., Herman, T., Simon, E. S., & Hausdorff, J. M. (2007). Effects of Pharmacological Therapy on Gait and Cognitive Function in Depressed Patients. Clinical Neuropharmacology, 30, 63-71.

[24]   Pan, M., Li, Z., Yeung, V., & Xu, R. J. (2010). Dietary Supplementation of Soy Germ Phytoestrogens or Estradiol Improves Spatial Memory Performance and Increases Gene Expression of BDNF, TrkB Receptor and Synaptic Factors in Ovariectomized Rats. Nutrition & Metabolism, 7, 75-85.

[25]   Potyk, D. (2005). Treatments for Alzheimer Disease. South Med J.

[26]   Raap, D. K., DonCarlos, L., Garcia, F., Muma, N. A., Wolf, W. A., Battaglia, G. et al. (2000). Estrogen Desensitizes 5-HT1A Receptors and Reduces Levels of Gz, Gi1 and Gi3 Proteins in the Hypothalamus. Neuropharmacology, 39, 1823-1832.

[27]   Rehavi, M., Attali, G., Gil-Ad, I., & Weizman, A. (2000). Suppression of Serum Gonadal Steroids in Rats by Chronic Treat- ment with Dopamine and Serotonin Reuptake Inhibitors. European Neuropsychopharmacology, 10, 145-150.

[28]   Savaskan, E., Müller, S. E., Böhringer, A., Schulz, A., & Schächinger, H. (2008). Antidepressive Therapy with Escitalopram Improves Mood, Cognitive Symptoms, and Identity Memory for Angry Faces in Elderly Depressed Patients. International Journal of Neuropsychopharmacology, 11, 381-388.

[29]   Shaw, N. D., Srouji, S. S., Histed, S. N., & Hall, J. E. (2011). Differential Effects of Aging on Estrogen Negative and Positive Feedback. American Journal of Physiology-Endocrinology and Metabolism, 301, E351-E355.

[30]   Shumaker, S. A., Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K. et al. (2003). Estrogen plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women’s Health Initiative Memory Study: A Randomized Controlled Trial. JAMA, 289, 2651-2662.

[31]   Soules, M. R., Sherman, S., Parrott, E., Rebar, R., Santoro, N., Utian, W., & Woods, N. (2001). Executive Summary: Stages of Reproductive Aging Workshop (STRAW). Climacteric, 4, 267-272.

[32]   Tang, M. X., Jacobs, D., Stern, Y., Marder, K., Schofield, P., Gurland, B. et al. (1996). Effect of Oestrogen during Menopause on Risk and Age at Onset of Alzheimer’s Disease. The Lancet, 348, 429-432.

[33]   Taylor, G. T., Farr, S., Klinga, K., & Weiss, J. (2004). Chronic Fluoxetine Suppresses Circulating Estrogen and the Enhanced Spatial Learning of Estrogen-Treated Ovariectomized Rats. Psychoneuroendocrinology, 29, 1241-1249.

[34]   Trivedi, M. H., Rush, A. J., Wisniewski, S. R. et al. (2006). Evaluation of Outcomes with Citalopram for Depression Using Measurement Based Care in STAR*D: Implications for Clinical Practice. American Journal of Psychiatry, 163, 28-40.

[35]   Uher, R., Maier, W., Hauser, J., Marusic, A., Schmael, C., Mors, O. et al. (2009a). Differential Efficacy of Escitalopram and Nortriptyline on Dimensional Measures of Depression. British Journal of Psychiatry, 194, 252-259.

[36]   Vinet, J., Carra, S., Blom, J. M. C., Brunello, N., Barden, N., & Tascedda, F. (2004). Chronic Treatment with Desipramine and Fluoxetine Modulate BDNF, CaMKKα and CaMKKβ mRNA Levels in the Hippocampus of Transgenic Mice Expressing Antisense RNA against the Glucocorticoid Receptor. Neuropharmacology, 47, 1062-1069.

[37]   Welt, C. K., Pagan, Y. L., Smith, P. C., Rado, K. B., & Hall, J. E. (2003). Control of Follicle-Stimulating Hormone by Estradiol and the Inhibins: Critical Role of Estradiol at the Hypothalamus during the Luteal-Follicular Transition. Journal of Clinical Endocrinology & Metabolism, 88, 1766-1771.

[38]   Wong, A., Xiong, Y. Y., Kwan, P. W., Chan, A. Y. Y., Lam, W. W. M., Wang, K. et al. (2009). The Validity, Reliability and Clinical Utility of the Hong Kong Montreal Cognitive Assessment (HK-MoCA-CV) in Patients with Cerebral Small Vessel Disease. Dementia and Geriatric Cognitive Disorders, 28, 81-87.

[39]   Writing Group for the WHI Investigators (2002). Risks and Benefits of Estrogen plus Progestin in Healthy Postmenopausal Women: Principal Results from the Women’s Health Initiative Randomized Controlled Trial. JAMA, 288, 321-333.

[40]   Wroolie, T. E., Williams, K. E., Keller, J., Zappert, L. N., Shelton, S. D., Kenna, H. A. et al. (2006). Mood and Neuropsychological Changes in Women with Midlife Depression Treated with Escitalopram. Journal of Clinical Psychopharmacology, 26, 361-366.

[41]   Yasui-Furukori, N., Tsuchimine, S., Nakagami, T., Fujii, A., Sato, Y., Tomita, T. et al. (2011). Association between Plasma Paroxetine Concentration and Changes in Plasma Brain-Derived Neurotrophic Factor Levels in Patients with Major Depressive Disorder. Human Psychopharmacology, 26, 194-200.

[42]   Zanardi, R., Rossini, D., Magri, L., Malaguti, A., Colombo, C., & Smeraldi, E. (2007). Response to SSRIs and Role of the Hormonal Therapy in Post-Menopausal Depression. European Neuropsychopharmacology, 17, 400-405.

[43]   Zec, R. F., & Trivendi, M. A. (2002). The Effects of Estrogen Replacement Therapy on Neuropsychological Function in Postmenopausal Women with and without Dementia: A Critical and Theoretical Review. Neuropsychology Review, 12, 65-109.

[44]   Zhang, L. X., & Liu, X. Q. (2008). The Preliminary Application of Montreal Cognitive Assessment of Chinese Version in the Older People in Guangzhou. Chinese Journal of Gerontology, 28, 1632-1634.

[45]   Zheng, Y. P., Zhao, J. P., Phillips, M., Liu, J. B., Cai, M. F., Sun, S. Q., & Huang, M. F. (1988). Validity and Reliability of the Chinese Hamilton Depression Rating Scale. British Journal of Psychiatry, 152, 660-664.

[46]   Zhou, B., Sun, X., Zhang, M., Deng, Y. H., & Hu, J. J. (2012). The Symptomatology of Climacteric Syndrome: Whether Associated with the Physical Factors Or Psychological Disorder in Perimenopausal/Postmen-Opausal Patients with Anxiety-Depression Disorder. Archives of Gynecology and Obstetrics, 285, 1345-1352.

[47]   Zhou, J., Zhang, H. B., Cohen, R. S., & Pandey, S. C. (2005). Effects of Estrogen Treatment on Expression of Brain-Derived Neurotrophic Factor and cAMP Response Element-Binding Protein Expression and Phosphorylation in Rat Amygdalold and Hippocampal Structures. Neuroendocrinology, 81, 294-310.